CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for CinCor Pharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

CinCor Pharma Inc
230 THIRD AVE., 6TH FLOOR
Phone: (302) 658-7581p:302 658-7581 WALTHAM, MA  02451  United States Fax: (302) 655-5049f:302 655-5049
This company was Merged or Acquired on 2/24/2023.
This company ceased filing statements with the SEC on 3/6/2023.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CIN-107 is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland. CIN-107 has been designed to use a differentiated mechanism of action, direct inhibition of aldosterone synthase production, with the target of providing an improved treatment for patients suffering from hypertension, or high blood pressure. In addition to hypertension, the Company is developing CIN-107 for the treatment of primary aldosteronism (PA) and exploring its utility in ameliorating complications of chronic kidney disease (CKD). It also exploring its utility in ameliorating complications of CKD. It is conducting a Phase II clinical trial, which it refers to as its BrigHtn trial.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202212/31/2021YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board James I.Healy 57 5/1/2019 5/1/2019
Chief Executive Officer, Director MarcDe Garidel 64 7/1/2021 7/1/2021
Chief Financial Officer, Executive Vice President Michael W.Kalb 52 11/4/2022 11/4/2022
6 additional Officers and Directors records available in full report.

General Information
Number of Employees: 19 (As of 9/30/2022)
Outstanding Shares: 43,764,323 (As of 11/3/2022)
Shareholders: 26
Stock Exchange: NASD
Federal Tax Id: 364931245
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, March 31, 2024